Risk factors for progression of chronic kidney disease in the EPPIC trials and the effect of AST-120

BACKGROUND: Two randomized, double-blind, placebo-controlled trials (EPPIC-1 and EPPIC-2) investigated the efficacy and safety of AST-120, an oral spherical carbon adsorbent, in adults with chronic kidney disease (CKD). While the benefit of adding AST-120 to standard therapy was not supported by the...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Clin Exp Nephrol
Hlavní autoři: Schulman, Gerald, Berl, Tomas, Beck, Gerald J., Remuzzi, Giuseppe, Ritz, Eberhard, Shimizu, Miho, Kikuchi, Mami, Shobu, Yuko
Médium: Artigo
Jazyk:Inglês
Vydáno: Springer Singapore 2017
Témata:
Original Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5838144/
https://ncbi.nlm.nih.gov/pubmed/28741050
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10157-017-1447-0
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky